The Expression of bcl-2, CD44 and p53 in Prostatic Adenocarcinoma.
- Author:
Byung Tae LEE
1
;
Choal Hee PARK
;
Kwan Kyu PARK
Author Information
1. Department of Urology, Keimyung University School of Medicine, Taegu, Korea.
- Publication Type:Original Article
- Keywords:
Prostate cancer;
bcl-2;
CD44;
p53
- MeSH:
Adenocarcinoma*;
Biopsy;
Disease Progression;
Humans;
Male;
Prostatic Neoplasms;
Transurethral Resection of Prostate
- From:Korean Journal of Urology
1998;39(12):1229-1235
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We evaluated the associations between the expression of bcl-2, CD44, p53 and tumor progression in prostate cancer. MATERIALS AND METHODS: Samples of prostatic tissue from 36 men with histologically confirmed prostate cancer were obtained by biopsy or transurethral prostatectomy, and we examined the expression of bcl-2, CD44, p53 using immunohistochemical staining and related their expression with the stage, grade, disease progression. RESULTS: Ten of 23 tumors were positive for bcl-2, 10 of 20 negative for CD44 and 11 of 16 positive for p53 had progression. Nine of 16 tumors positive for p53 were poorly differentiated compared with 6 of 20 negative for p53(p < 0.05). Also, 13 of 20 tumors negative for CD44 were poorly differentiated compared with 2 of 16 positive for CD44(p < 0.05). A significant number of patients positive for p53 progressed and had shorter time to progression compared to those negative for p53(p < 0.05). Bcl-2 staining was not correlated with grade, clinical stage and tumor progression. p53 staining was not correlated with clinical stage, whereas CD44 was not correlated with clinical stage and tumor progression. CONCLUSIONS: There was an association between aggressive behaviour of prostate cancer and the increasing expression of p53. This study confirmed that the expression of p53 had significant impact on the disease progression regardless of stage in the prostate cancer however, the expression CD44 and bcl-2 had no role in the progression and clinical stage of the prostate cancer.
